Skip to content

Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III (LONG-DES-III)

Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III: Sirolimus vs. Everolimus-eluting Stent

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01078038
Acronym
LONG-DES-III
Enrollment
451
Registered
2010-03-02
Start date
2008-06-30
Completion date
2010-08-31
Last updated
2012-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

Coronary Artery Disease, Stent

Brief summary

This randomized study is a multi-center, randomized, study to compare the efficacy of sirolimus versus everolimus-eluting stent implantation for long coronary lesions.

Detailed description

Following angiography, patients with significant diameter stenosis \>50% and lesion length (\> 25mm) requiring single or multiple long-stent placement (total stent length \>28mm) by visual estimation and eligible for LONG-DES III trial inclusion and exclusion criteria will be randomized 1:1 to a) sirolimus-eluting and b) everolimus-eluting stent by the stratified randomization method.

Interventions

DEVICECypher

Sirolimus-eluting stent implantation

DEVICEXience V

Everolimus-eluting Stent implantation

Sponsors

CardioVascular Research Foundation, Korea
CollaboratorOTHER
Seung-Jung Park
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* The patient must be at least 18 years of age. * Significant native coronary artery stenosis (\>50% by visual estimate) with lesion length of more than 25mm, which requiring single or multiple long stent placement (\>=28mm) * Patients with silent ischemia, stable or unstable angina pectoris, ad Non-ST-elevation myocardial infarction * The patient or guardian agrees to the study protocol and the schedule of clinical and angiographic follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.

Exclusion criteria

* Any contraindication to any of the following medications: aspirin, heparin, clopidogrel, stainless steel, contrast agents, sirolimus, or everolimus. * An elective surgical procedure is planned that would necessitate interruption of antiplatelet drugs during the first 6 months post enrollment. * Acute ST-segment-elevation MI or cardiogenic shock * Terminal illness with life expectancy \<1 year * Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period. * In-stent restenosis at target vessel (either bare metal stent or drug-eluting stent segment, non-target vessel ISR is permitted) * Patients with EF\<30%. * Serum creatinine level \>=3.0mg/dL or dependence on dialysis. * Patients with left main stem stenosis (\>50% by visual estimate).

Design outcomes

Primary

MeasureTime frame
In-segment late luminal loss9 month follow-up

Secondary

MeasureTime frameDescription
Cardiac death1 year
Myocardial infarction (MI)1 year
Composite of death or MI1 year
Composite of cardiac death or MI1 year
Target vessel revascularization (ischemia-driven and clinically-driven)1 year
Target lesion revascularization (ischemia-driven and clinically-driven)1 year
Target-vessel failure (death from any cause, myocardial infarction, and ischemic-driven target-vessel revascularization)1 year
All Deathone month
In-stent late loss at 9 month angiographic follow-upat 9 month angiographic follow-up
In-stent and in-segment restenosis at 9 month angiographic follow-upat 9 month angiographic follow-up
Angiographic pattern of restenosis at 9 month angiographic follow-upat 9 month angiographic follow-up
Volume of intimal hyperplasia at 9 month IVUS follow-up (sub-study)at 9 month angiographic follow-up
Incidence of late stent malapposition at 9 month IVUS follow-up (sub-study)at 9 month angiographic follow-up
Procedural success defined as achievement of a final diameter stenosis of <30% by QCA using any percutaneous method, without the occurrence of death, Q wave MI, or repeat revascularization of the target lesion during the hospital stay.3 days in averageAt discharge from the index hospitalization, participants will be followed for the duration of hospital stay, an expected average of 3 days.
Stent thrombosis (ARC criteria)1 year

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026